From the Center for Evaluation and Sociomedical Research (CAG, GCC, ADHV), University of Puerto Rico, San Juan, Puerto Rico; Friends Research Institute, Inc. (TWK, MSG, RPS), Social Research Center, Baltimore, MD; Division of Criminology, Criminal Justice, and Social Policy (TWK), University of Baltimore, Baltimore, MD; Correctional Health Services Corporation (CAA, ICR), Department of Correction and Rehabilitation, Rio Grande, Puerto Rico; Open Society Institute-Baltimore (RPS), Baltimore, MD.
J Addict Med. 2007 Sep;1(3):126-32. doi: 10.1097/ADM.0b013e31814b8880.
The following study, conducted in Puerto Rico, examined the feasibility of providing daily buprenorphine-naloxone (bup-nx) in prison and on release to 45 male inmates with histories of heroin addiction. Participants were assessed at study entry and at 1 month after release (N = 42; 93.3% follow-up rate). Treatment completers compared with noncompleters had significantly greater reductions in self-reported heroin use, cocaine use, and crime and were less likely to be opioid-positive according to urine drug testing. Despite study limitations, the short-term outcomes of this study suggest that bup-nx may contribute to reductions in readdiction to heroin and in criminal activities among re-entering male prisoners.
这项在波多黎各开展的研究旨在评估在监狱内以及释放后向 45 名有海洛因成瘾史的男性囚犯提供丁丙诺啡-纳洛酮（丁丙诺啡-纳洛酮）的可行性。研究人员在研究开始时和释放后 1 个月对参与者进行评估（N = 42；93.3%的随访率）。与未完成治疗的参与者相比，完成治疗的参与者报告的海洛因使用、可卡因使用和犯罪行为明显减少，根据尿液药物检测，阿片类药物阳性的可能性也较小。尽管存在研究限制，但这项研究的短期结果表明，丁丙诺啡-纳洛酮可能有助于减少重新入狱的男性囚犯对海洛因的复吸和犯罪活动。
